<?xml version="1.0" encoding="UTF-8"?>
<p>Liposomal AmB is highly effective when used in combination with other drugs. This pharmaceutical preparation was recommended by WHO as the preferred treatment for cryptococcal meningitis [
 <xref rid="pntd.0007964.ref029" ref-type="bibr">29</xref>]. However, the high prices and unavailability of liposomal AmB in several countries have created major barriers to access to the most recommended treatment—as recognized by WHO itself—in developing countries. Liposomal AmB is registered and available for use (at high cost) in only 6 of 116 developing countries where fungal meningitis is a public health problem [
 <xref rid="pntd.0007964.ref011" ref-type="bibr">11</xref>]. Prices are impeditive in many countries, revealing an unquestionable market failure.
</p>
